BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 24035442)

  • 1. Serum granulysin as a possible key marker of the activity of alopecia areata.
    Ono S; Otsuka A; Yamamoto Y; Kataoka TR; Koyanagi I; Miyachi Y; Kabashima K
    J Dermatol Sci; 2014 Jan; 73(1):74-9. PubMed ID: 24035442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase.
    Ito T; Hashizume H; Shimauchi T; Funakoshi A; Ito N; Fukamizu H; Takigawa M; Tokura Y
    J Dermatol Sci; 2013 Feb; 69(2):140-7. PubMed ID: 23312578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of interleukin-17- producing cells in different clinical types of alopecia areata.
    Tojo G; Fujimura T; Kawano M; Ogasawara K; Kambayashi Y; Furudate S; Mizuashi M; Aiba S
    Dermatology; 2013; 227(1):78-82. PubMed ID: 24008930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study.
    Simonetti O; Lucarini G; Bernardini ML; Simoncini C; Biagini G; Offidani A
    Br J Dermatol; 2004 May; 150(5):940-8. PubMed ID: 15149507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-gamma-deficient mice are resistant to the development of alopecia areata.
    Freyschmidt-Paul P; McElwee KJ; Hoffmann R; Sundberg JP; Vitacolonna M; Kissling S; Zöller M
    Br J Dermatol; 2006 Sep; 155(3):515-21. PubMed ID: 16911275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lesional infiltration of mast cells, Langerhans cells, T cells and local cytokine profiles in alopecia areata.
    Zhang X; Zhao Y; Ye Y; Li S; Qi S; Yang Y; Cao H; Yang J; Zhang X
    Arch Dermatol Res; 2015 May; 307(4):319-31. PubMed ID: 25638328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy.
    Oba MC; Askin O; Balci Ekmekci O; Serdaroglu S
    J Cosmet Dermatol; 2021 Mar; 20(3):971-975. PubMed ID: 32808476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of CXCL1, CXCL9, CXCL10 and CXCL12 chemokines in alopecia areata.
    Zainodini N; Hassanshahi G; Arababadi MK; Khorramdelazad H; Mirzaei A
    Iran J Immunol; 2013 Mar; 10(1):40-6. PubMed ID: 23502337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-gamma in alopecia areata.
    Arca E; Muşabak U; Akar A; Erbil AH; Taştan HB
    Eur J Dermatol; 2004; 14(1):33-6. PubMed ID: 14965793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum anti-Fcgamma receptor autoantibodies in patients with alopecia areata.
    Kuwano Y; Fujimoto M; Watanabe R; Asashima N; Nakashima H; Ohno H; Yano S; Yazawa N; Okochi H; Tamaki K
    Arch Dermatol Res; 2007 Mar; 298(10):493-8. PubMed ID: 17124586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alopecia areata in C3H/HeJ mice involves leukocyte-mediated root sheath disruption in advance of overt hair loss.
    McElwee KJ; Silva K; Boggess D; Bechtold L; King LE; Sundberg JP
    Vet Pathol; 2003 Nov; 40(6):643-50. PubMed ID: 14608017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulysin-producing cytotoxic T cells in the mucocutaneous lesions of Behçet disease: a distinct inflammatory response from erythema nodosum.
    Yamasaki O; Morizane S; Aochi S; Ogawa K; Oono T; Iwatsuki K
    Clin Exp Dermatol; 2011 Dec; 36(8):903-7. PubMed ID: 21883401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of lipid peroxidation, oxidant/antioxidant status, and serum nitric oxide levels in alopecia areata.
    Koca R; Armutcu F; Altinyazar C; Gürel A
    Med Sci Monit; 2005 Jun; 11(6):CR296-299. PubMed ID: 15917721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased retinol-binding protein (RBP) 4 and anti-RBP4 antibody in alopecia areata.
    Ahn KJ; Choi EA; Kim J; Lee JH; Lee KH; Bang D; Cho SB
    Br J Dermatol; 2011 Oct; 165(4):837-44. PubMed ID: 21711327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistological study of the development of the cellular infiltrate in the pelage follicles of the DEBR model for alopecia areata.
    Zhang JG; Oliver RF
    Br J Dermatol; 1994 Apr; 130(4):405-14. PubMed ID: 7910477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum thymus and activation-regulated chemokine as disease activity and response biomarker in alopecia areata.
    Inui S; Noguchi F; Nakajima T; Itami S
    J Dermatol; 2013 Nov; 40(11):881-5. PubMed ID: 24102731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alopecia areata: infiltration of Th17 cells in the dermis, particularly around hair follicles.
    Tanemura A; Oiso N; Nakano M; Itoi S; Kawada A; Katayama I
    Dermatology; 2013; 226(4):333-6. PubMed ID: 23838575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hair follicle structures targeted by antibodies in patients with alopecia areata.
    Tobin DJ; Hann SK; Song MS; Bystryn JC
    Arch Dermatol; 1997 Jan; 133(1):57-61. PubMed ID: 9006373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata.
    Tembhre MK; Sharma VK
    Br J Dermatol; 2013 Sep; 169(3):543-8. PubMed ID: 23607748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata.
    Bertolini M; Zilio F; Rossi A; Kleditzsch P; Emelianov VE; Gilhar A; Keren A; Meyer KC; Wang E; Funk W; McElwee K; Paus R
    PLoS One; 2014; 9(5):e94260. PubMed ID: 24832234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.